| SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE |
The
following table sets forth the computation of the basic and diluted net loss per share:
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE
| | |
September 30,
2025 | | |
September 30,
2024 | | |
September 30,
2025 | | |
September 30,
2024 | |
| | |
Three months ended | | |
Nine months ended | |
| | |
September 30,
2025 | | |
September 30,
2024 | | |
September 30,
2025 | | |
September 30,
2024 | |
| | |
| | |
| | |
| | |
| |
| Numerator: | |
| | | |
| | | |
| | | |
| | |
| Net loss | |
$ | (4,459,764 | ) | |
$ | (10,092,312 | ) | |
$ | (11,973,902 | ) | |
$ | (14,185,887 | ) |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted average shares outstanding | |
| 8,367,774 | | |
| 4,517,125 | | |
| 6,673,074 | | |
| 4,169,490 | |
| Net loss per share, basic and diluted | |
$ | (0.53 | ) | |
$ | (2.23 | ) | |
$ | (1.79 | ) | |
$ | (3.40 | ) |
|
The
following table sets forth the computation of the basic and diluted net loss per share:
SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE
| | |
Year ended
December 31, 2024 | | |
Period from March 16, 2023 (inception) through December 31, 2023 | |
| | |
| | |
| |
| Numerator: | |
| | | |
| | |
| Net loss | |
$ | (23,753,863 | ) | |
$ | (3,793,585 | ) |
| Denominator: | |
| | | |
| | |
| Weighted average shares outstanding | |
| 4,282,194 | | |
| 4,039,651 | |
| Net loss per share, basic and diluted | |
$ | (5.5 | ) | |
$ | (0.90 | ) |
|
| SCHEDULE OF ANTI-DILUTIVE EFFECT |
The
following potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders
for the periods presented, because including them would have had an anti-dilutive effect:
SCHEDULE OF ANTI-DILUTIVE EFFECT
| | |
September 30,
2025 | | |
September 30,
2024 | |
| Unvested common stock – restricted shares (Note 5) | |
| - | | |
| 12,541 | |
| Restricted Stock options | |
| 31,377 | | |
| 85,166 | |
| Restricted Stock Units | |
| 151,701 | | |
| 328,191 | |
| Performance Stock units | |
| 50,658 | | |
| 50,658 | |
| Public warrants | |
| 486,413 | | |
| 486,413 | |
| Private warrants | |
| 556,666 | | |
| 556,666 | |
| Inducement warrants | |
| 958,400 | | |
| - | |
| Short term loan warrants | |
| 86,591 | | |
| - | |
| Private placement warrants | |
| 6,425 | | |
| - | |
| Potentially dilutive shares | |
| 958,400 | | |
| - | |
| * |
The
Sponsor Earnout Shares (as defined in the Business Combination Agreement) were not included for purposes of calculating the number
of diluted shares outstanding as of September 30, 2025, as the Sponsor Earnout Shares remain contingently forfeitable, as the conditions
have not been met. |
|
The
following potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders
for the periods presented, because including them would have had an anti-dilutive effect:
SCHEDULE
OF ANTI-DILUTIVE EFFECT
| | |
December 31, 2024 | | |
December 31, 2023 | |
| Unvested common stock – restricted shares (Note 8) | |
| 6,270 | | |
| 164,050 | |
| Restricted stock options | |
| 70,999 | | |
| - | |
| Restricted stock units | |
| 248,640 | | |
| - | |
| Performance stock units | |
| 50,659 | | |
| - | |
| Public warrants | |
| 4,864,133 | | |
| - | |
| Private placement warrants | |
| 5,566,667 | | |
| - | |
| * |
|
The Sponsor Earnout Shares
(as defined in the Business Combination Agreement) were not included for purposes of calculating the number of diluted shares outstanding
as of December 31, 2024, as the Sponsor earnout shares remain contingently forfeitable, as the conditions have not been met |
|